Skip to content

Study Accelerometer Signals to Measure Daily Activities (SASMDA)

Study Accelerometer Signals to Measure Daily Activities: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01617512
Enrollment
30
Registered
2012-06-12
Start date
2012-02-29
Completion date
2013-07-31
Last updated
2014-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Disorders

Brief summary

The purpose of this study is to determine if it is possible to identify activities in the daily accelerometer measures of a person with urinary disorders.

Interventions

DEVICELIS302DL accelerometer

Recording for 24 hours accelerations related to daily physical activity of the patient.

Sponsors

TIMC-IMAG
CollaboratorOTHER
Laboratory TIMA
CollaboratorUNKNOWN
Clinical Investigation Centre for Innovative Technology Network
CollaboratorNETWORK
AdministrateurCIC
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* man * patients fitted with artificial urinary sphincter * patients affiliated to social security or similar regime

Exclusion criteria

* patient do not speak french * patient unable to express his consent * patient hospitalize without consent * patient under legal protection * patient deprived of liberty

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with urinary disorders for which it is possible to identify automatically activities among all the daily accelerometer data.6 monthsIntrinsic characteristics (sensitivity, specificity, ROC curve) of the test for detecting in automated way the activities among all the daily accelerometer data

Secondary

MeasureTime frameDescription
Score of satisfaction with the use of the medical device, assessed by the patients6 monthsScore between 0 and 10, takes into account the feasibility of the proposed approach and the patient felt the importance of this feasibility.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026